These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21616918)

  • 21. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Preliminary results of selective combined therapy for patients with urinary bladder cancer].
    Zharinov GM; Agafonova MV; Tarazov PG; Suvorova IuV; Kozlov AA
    Vopr Onkol; 2003; 49(5):636-8. PubMed ID: 14682138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow up of patients with invasive bladder carcinoma receiving combined cisplatin-based intra-arterial chemotherapy and radiotherapy.
    Mori K; Nomata K; Noguchi M; Eguchi J; Hayashi N; Kanetake H
    Int J Urol; 2007 Jul; 14(7):591-4. PubMed ID: 17645599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined therapy for patients with invasive bladder cancer].
    Startsev VIu; Karelin MI
    Vopr Onkol; 2003; 49(2):235-8. PubMed ID: 12785212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
    Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
    Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).
    Lagrange JL; Bascoul-Mollevi C; Geoffrois L; Beckendorf V; Ferrero JM; Joly F; Allouache N; Bachaud JM; Chevreau C; Kramar A; Chauvet B;
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):172-8. PubMed ID: 20385453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer death from non-muscle invasive bladder cancer: report of the Japanese Urological Association of data from the 1999-2001 registry in Japan.
    Okajima E; Fujimoto H; Mizutani Y; Kikuchi E; Koga H; Hinotsu S; Shinohara N; Miki T;
    Int J Urol; 2010 Nov; 17(11):905-12. PubMed ID: 20969637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy.
    Weiss C; Rödel F; Ott O; Engehausen DG; Papadopoulos T; Sauer R; Rödel C
    Strahlenther Onkol; 2007 Oct; 183(10):552-6. PubMed ID: 17896086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bladder sparing approach to muscle invasive carcinoma of the bladder.
    Marino R; Wajsman Z
    Prog Clin Biol Res; 1990; 353():175-8. PubMed ID: 2217416
    [No Abstract]   [Full Text] [Related]  

  • 32. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
    Müller AC; Diestelhorst A; Kuhnt T; Kühn R; Fornara P; Scholz HJ; Dunst J; Zietman AL
    Strahlenther Onkol; 2007 Apr; 183(4):177-83. PubMed ID: 17406798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.
    Sauer R; Birkenhake S; Kühn R; Wittekind C; Schrott KM; Martus P
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):121-7. PubMed ID: 9422567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of tumor recurrence: a strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer.
    Tanaka N; Kikuchi E; Matsumoto K; Miyajima A; Nakagawa K; Oya M
    J Urol; 2011 Feb; 185(2):450-5. PubMed ID: 21167533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
    Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
    Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.